Rapid resistance profiling of SARS-CoV-2 protease inhibitors

Mostrar otras versiones (1)

Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (M(pro)) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001...

Descripción completa

Detalles Bibliográficos
Autores principales: Moghadasi, Seyed Arad, Biswas, Rayhan G., Harki, Daniel A., Harris, Reuben S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055523/
https://www.ncbi.nlm.nih.gov/pubmed/36993515
http://dx.doi.org/10.21203/rs.3.rs-2627723/v1
_version_ 1785015891959742464
author Moghadasi, Seyed Arad
Biswas, Rayhan G.
Harki, Daniel A.
Harris, Reuben S.
author_facet Moghadasi, Seyed Arad
Biswas, Rayhan G.
Harki, Daniel A.
Harris, Reuben S.
author_sort Moghadasi, Seyed Arad
collection PubMed
description Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (M(pro)) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001. The results reveal distinct resistance mechanisms (“fingerprints”) and indicate that these next-generation drugs have the potential to be effective against nirmatrelvir-resistant variants and vice versa.
format Online
Article
Text
id pubmed-10055523
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Journal Experts
record_format MEDLINE/PubMed
spelling pubmed-100555232023-03-30 Rapid resistance profiling of SARS-CoV-2 protease inhibitors Moghadasi, Seyed Arad Biswas, Rayhan G. Harki, Daniel A. Harris, Reuben S. Res Sq Article Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (M(pro)) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001. The results reveal distinct resistance mechanisms (“fingerprints”) and indicate that these next-generation drugs have the potential to be effective against nirmatrelvir-resistant variants and vice versa. American Journal Experts 2023-03-15 /pmc/articles/PMC10055523/ /pubmed/36993515 http://dx.doi.org/10.21203/rs.3.rs-2627723/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Moghadasi, Seyed Arad
Biswas, Rayhan G.
Harki, Daniel A.
Harris, Reuben S.
Rapid resistance profiling of SARS-CoV-2 protease inhibitors
title Rapid resistance profiling of SARS-CoV-2 protease inhibitors
title_full Rapid resistance profiling of SARS-CoV-2 protease inhibitors
title_fullStr Rapid resistance profiling of SARS-CoV-2 protease inhibitors
title_full_unstemmed Rapid resistance profiling of SARS-CoV-2 protease inhibitors
title_short Rapid resistance profiling of SARS-CoV-2 protease inhibitors
title_sort rapid resistance profiling of sars-cov-2 protease inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055523/
https://www.ncbi.nlm.nih.gov/pubmed/36993515
http://dx.doi.org/10.21203/rs.3.rs-2627723/v1
work_keys_str_mv AT moghadasiseyedarad rapidresistanceprofilingofsarscov2proteaseinhibitors
AT biswasrayhang rapidresistanceprofilingofsarscov2proteaseinhibitors
AT harkidaniela rapidresistanceprofilingofsarscov2proteaseinhibitors
AT harrisreubens rapidresistanceprofilingofsarscov2proteaseinhibitors

Ejemplares similares